Last reviewed · How we verify

Dehydroepiandrosterone (DHEA)

Boston Children's Hospital · FDA-approved active Small molecule

Dehydroepiandrosterone (DHEA) is a Steroid hormone / Prohormone Small molecule drug developed by Boston Children's Hospital. It is currently FDA-approved for Systemic lupus erythematosus (SLE), Age-related conditions and immune dysfunction. Also known as: Prasterone.

DHEA is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating immune function and metabolic processes.

DHEA is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating immune function and metabolic processes. Used for Systemic lupus erythematosus (SLE), Age-related conditions and immune dysfunction.

At a glance

Generic nameDehydroepiandrosterone (DHEA)
Also known asPrasterone
SponsorBoston Children's Hospital
Drug classSteroid hormone / Prohormone
TargetAndrogen receptor, Estrogen receptor (indirect via peripheral conversion)
ModalitySmall molecule
Therapeutic areaEndocrinology, Immunology, Rheumatology
PhaseFDA-approved

Mechanism of action

DHEA is produced by the adrenal glands and serves as a prohormone that can be converted peripherally to testosterone and estradiol. It plays roles in immune regulation, bone metabolism, and potentially in treating age-related conditions and certain autoimmune disorders. The exact mechanisms of therapeutic benefit in specific conditions remain incompletely understood but involve both hormonal and immunomodulatory pathways.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dehydroepiandrosterone (DHEA)

What is Dehydroepiandrosterone (DHEA)?

Dehydroepiandrosterone (DHEA) is a Steroid hormone / Prohormone drug developed by Boston Children's Hospital, indicated for Systemic lupus erythematosus (SLE), Age-related conditions and immune dysfunction.

How does Dehydroepiandrosterone (DHEA) work?

DHEA is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating immune function and metabolic processes.

What is Dehydroepiandrosterone (DHEA) used for?

Dehydroepiandrosterone (DHEA) is indicated for Systemic lupus erythematosus (SLE), Age-related conditions and immune dysfunction.

Who makes Dehydroepiandrosterone (DHEA)?

Dehydroepiandrosterone (DHEA) is developed and marketed by Boston Children's Hospital (see full Boston Children's Hospital pipeline at /company/boston-children-s-hospital).

Is Dehydroepiandrosterone (DHEA) also known as anything else?

Dehydroepiandrosterone (DHEA) is also known as Prasterone.

What drug class is Dehydroepiandrosterone (DHEA) in?

Dehydroepiandrosterone (DHEA) belongs to the Steroid hormone / Prohormone class. See all Steroid hormone / Prohormone drugs at /class/steroid-hormone-prohormone.

What development phase is Dehydroepiandrosterone (DHEA) in?

Dehydroepiandrosterone (DHEA) is FDA-approved (marketed).

What are the side effects of Dehydroepiandrosterone (DHEA)?

Common side effects of Dehydroepiandrosterone (DHEA) include Acne, Hirsutism, Voice deepening, Mood changes, Headache.

What does Dehydroepiandrosterone (DHEA) target?

Dehydroepiandrosterone (DHEA) targets Androgen receptor, Estrogen receptor (indirect via peripheral conversion) and is a Steroid hormone / Prohormone.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing